Proteomics International Laboratories Ltd (ASX: PIQ), a medical technology company specializing in precision medicine and predictive diagnostics, has made significant strides in its business activities during the three months to June 2023. One notable achievement is the exclusive license agreement with Sonic Healthcare USA to bring the PromarkerD test for diabetic kidney disease to the United States. This partnership aims to extend the reach and adoption of PromarkerD in the US market, benefiting millions of diabetes patients.
Additionally, a drug treatment study involving canagliflozin, a diabetes medicine, showed a reduction in PromarkerD risk scores for patients with type 2 diabetes. This research, published in the Journal of Clinical Medicine, supports the effectiveness of the PromarkerD test. To support the PromarkerD USA and global rollout, Proteomics International expanded its Clinical Advisory Board, bringing in key opinion leaders in primary care diabetes education and management. The company has also made progress toward obtaining US reimbursement for PromarkerD, which is crucial for its coverage and reimbursement by private payers.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 20, 2024
Nov 20, 2024
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
